Evidence map›Paper›PMID 42569132›Full record

ArticleACS omega2026

Coumarin Conjugation as an Albumin-Binding Strategy to Modulate the Pharmacokinetics of FAPI Radiotracers.

Ju Xiong, Yifei Pei, Xiaoyi Guo, Yuchen Yang, Libing Wu, Liyan Fan, Hongwei Hou, Zhi Yang, Jinghong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ju XiongCenter for BioAnalytical Chemistry, Hefei National Laboratory of Physical Science at Microscale, University of Science and Technology of China, Hefei 230026, China.
Yifei PeiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.ORCID https://orcid.org/0009-0002-1403-7704
Xiaoyi GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Yuchen YangNew Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, China.
Libing WuBeijing Life Science Academy, Beijing 102209, China.
Liyan FanTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Hongwei HouBeijing Life Science Academy, Beijing 102209, China.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.ORCID https://orcid.org/0000-0003-2084-5193
Jinghong LiCenter for BioAnalytical Chemistry, Hefei National Laboratory of Physical Science at Microscale, University of Science and Technology of China, Hefei 230026, China.ORCID https://orcid.org/0000-0002-0750-7352

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) was a prominent target overexpressed in the stroma of various tumors. However, most current FAP-targeted radiotracers suffer from rapid systemic clearance and limited tumor retention, which limits their imaging contrast and therapeutic efficacy. In this study, we exploited diethylamino coumarin as a novel small-molecule albumin binder to optimize the pharmacokinetic profile of FAP-targeted radiopharmaceuticals. Two probes with different linker lengths, [

Identifiers

PMID42569132
PMCPMC13449004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.